Robert Naraghi, MD
Urology · Orange, CANPI 1306950043
Payments from drug & device makers
Across 53 payments — averaging $180.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organox Ltd$8K
- Veloxis Pharmaceuticals, Inc.$469
- Takeda Pharmaceuticals U.S.A., Inc.$295
- E.r. Squibb & Sons, L.L.C.$142
- Alnylam Pharmaceuticals Inc.$97
- Sanofi-aventis U.S. LLC$94
- plus $319 from 8 others
What the payments were for
- Speaking & faculty fees$6,22865%
- Travel & lodging$1,60217%
- Food & beverage$1,69618%
- Education$611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organox Ltd | 6 | $8,172 |
| Veloxis Pharmaceuticals, Inc. | 15 | $469 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $295 |
| E.r. Squibb & Sons, L.L.C. | 3 | $142 |
| Alnylam Pharmaceuticals Inc. | 3 | $97 |
| Sanofi-aventis U.S. LLC | 2 | $94 |
| Kyowa Kirin, Inc. | 3 | $87 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Johnson & Johnson | 3 | $40 |
| AbbVie(2 entities) | 2 | $32 |
| Merck | 1 | $31 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| AstraZeneca | 1 | $24 |
| Exact Sciences | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,588 in reported general payments places this provider in the 70th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Valganciclovir Hcl | 307 | $61,591 |
| Cinacalcet Hcl | 175 | $61,297 |
| Tacrolimus | 123 | $13,185 |
| Mycophenolic AcidMycophenolate Sodium | 74 | $12,417 |
| Itraconazole | 95 | $11,825 |
| Envarsus XrTacrolimus | 31 | $11,069 |
| SpsSodium Polystyrene Sulfon/Sorb | 86 | $6,836 |
| Novolog FlexpenInsulin Aspart | 50 | $6,515 |
| Tamsulosin Hcl | 689 | $5,913 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $5,822 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $5,040 |
| Mycophenolate Mofetil | 33 | $4,802 |
| RetacritEpoetin Alfa-Epbx | 11 | $4,697 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 65 | $3,984 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $3,313 |
Paid to pharmacies, not to this prescriber.
Other urology in Orange
- Edward UchioOrange$21.1M
- Ralph ClaymanOrange$3.9M
- Jaime LandmanOrange$851K
- Faysal YafiOrange$346K
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.